Literature DB >> 35187407

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma.

Borja Puertas1, María-Victoria Mateos1, Verónica González-Calle1.   

Abstract

Entities:  

Year:  2022        PMID: 35187407      PMCID: PMC8849396          DOI: 10.1097/HS9.0000000000000691

Source DB:  PubMed          Journal:  Hemasphere        ISSN: 2572-9241


× No keyword cloud information.
  8 in total

1.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

2.  Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Authors:  Ujjawal H Gandhi; Robert F Cornell; Arjun Lakshman; Zhubin J Gahvari; Elizabeth McGehee; Megan H Jagosky; Ridhi Gupta; William Varnado; Mark A Fiala; Saurabh Chhabra; Ehsan Malek; Joshua Mansour; Barry Paul; Alyssa Barnstead; Saranya Kodali; Amarendra Neppalli; Michaela Liedtke; Swapna Narayana; Kelly N Godby; Yubin Kang; Ankit Kansagra; Elvira Umyarova; Emma C Scott; Parameswaran Hari; Ravi Vij; Saad Z Usmani; Natalie S Callander; Shaji K Kumar; Luciano J Costa
Journal:  Leukemia       Date:  2019-03-11       Impact factor: 11.528

3.  Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Authors:  Sagar Lonial; Hans C Lee; Ashraf Badros; Suzanne Trudel; Ajay K Nooka; Ajai Chari; Al-Ola Abdallah; Natalie Callander; Nikoletta Lendvai; Douglas Sborov; Attaya Suvannasankha; Katja Weisel; Lionel Karlin; Edward Libby; Bertrand Arnulf; Thierry Facon; Cyrille Hulin; K Martin Kortüm; Paula Rodríguez-Otero; Saad Z Usmani; Parameswaran Hari; Rachid Baz; Hang Quach; Philippe Moreau; Peter M Voorhees; Ira Gupta; Axel Hoos; Eric Zhi; January Baron; Trisha Piontek; Eric Lewis; Roxanne C Jewell; Elisha J Dettman; Rakesh Popat; Simona Degli Esposti; Joanna Opalinska; Paul Richardson; Adam D Cohen
Journal:  Lancet Oncol       Date:  2019-12-16       Impact factor: 41.316

4.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Authors:  Jesus G Berdeja; Deepu Madduri; Saad Z Usmani; Andrzej Jakubowiak; Mounzer Agha; Adam D Cohen; A Keith Stewart; Parameswaran Hari; Myo Htut; Alexander Lesokhin; Abhinav Deol; Nikhil C Munshi; Elizabeth O'Donnell; David Avigan; Indrajeet Singh; Enrique Zudaire; Tzu-Min Yeh; Alicia J Allred; Yunsi Olyslager; Arnob Banerjee; Carolyn C Jackson; Jenna D Goldberg; Jordan M Schecter; William Deraedt; Sen Hong Zhuang; Jeffrey Infante; Dong Geng; Xiaoling Wu; Marlene J Carrasco-Alfonso; Muhammad Akram; Farah Hossain; Syed Rizvi; Frank Fan; Yi Lin; Thomas Martin; Sundar Jagannath
Journal:  Lancet       Date:  2021-06-24       Impact factor: 79.321

5.  Multiple myeloma: patient outcomes in real-world practice.

Authors:  Kwee Yong; Michel Delforge; Christoph Driessen; Leah Fink; Alain Flinois; Sebastian Gonzalez-McQuire; Reza Safaei; Lionel Karlin; Maria-Victoria Mateos; Marc S Raab; Paul Schoen; Michele Cavo
Journal:  Br J Haematol       Date:  2016-07-13       Impact factor: 6.998

6.  Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Authors:  Mehmet Kemal Samur; Mariateresa Fulciniti; Anil Aktas Samur; Abdul Hamid Bazarbachi; Yu-Tzu Tai; Rao Prabhala; Alejandro Alonso; Adam S Sperling; Timothy Campbell; Fabio Petrocca; Kristen Hege; Shari Kaiser; Hervé Avet Loiseau; Kenneth C Anderson; Nikhil C Munshi
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

7.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Authors:  Marcela V Maus; Sara Alexander; Michael R Bishop; Jennifer N Brudno; Colleen Callahan; Marco L Davila; Claudia Diamonte; Jorg Dietrich; Julie C Fitzgerald; Matthew J Frigault; Terry J Fry; Jennifer L Holter-Chakrabarty; Krishna V Komanduri; Daniel W Lee; Frederick L Locke; Shannon L Maude; Philip L McCarthy; Elena Mead; Sattva S Neelapu; Tomas G Neilan; Bianca D Santomasso; Elizabeth J Shpall; David T Teachey; Cameron J Turtle; Tom Whitehead; Stephan A Grupp
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

8.  KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Authors:  Sundar Jagannath; Yi Lin; Hartmut Goldschmidt; Donna Reece; Ajay Nooka; Alicia Senin; Paula Rodriguez-Otero; Ray Powles; Kosei Matsue; Nina Shah; Larry D Anderson; Matthew Streetly; Kimberly Wilson; Hoa Van Le; Arlene S Swern; Amit Agarwal; David S Siegel
Journal:  Blood Cancer J       Date:  2021-06-18       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.